Nasdaq · Healthcare
NEOGENOMICS INC (NEO)
As-reported financials and recent SEC filings for NEOGENOMICS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$727.3M
Net income
$-108.0M
Net margin
-14.9%
Diluted EPS
—
ROE
-12.9%
P/E (TTM)
—
Market cap
$1.85B
Debt / equity
0.4×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $727.3M | $660.6M | $591.6M | $509.7M | $484.3M |
| Gross profit | $314.3M | $290.1M | $244.6M | $187.9M | $187.1M |
| Operating income | $-115.9M | $-92.1M | $-107.7M | $-157.6M | $-118.8M |
| Net income | $-108.0M | $-78.7M | $-88.0M | $-144.3M | $-8.3M |
| Diluted EPS | — | — | — | — | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-25
View on EDGAR →32026-06-25
View on EDGAR →8-K2026-06-25
View on EDGAR →8-K2026-06-22
View on EDGAR →42026-06-17
View on EDGAR →8-K2026-06-17
View on EDGAR →1442026-06-15
View on EDGAR →8-K2026-06-15
View on EDGAR →Go deeper on NEO
Search NEOGENOMICS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.